PepTrackevidence-graded reference
MOTS-c
fig.1 — stylized molecular motif
Metabolic

MOTS-c

mitochondrial-derived peptide

Rising longevity/biohacker name; 'exercise mimetic'; first native human RCT (Phase 2a, NCT07505745) began Feb 2026.

Evidence
Danimal-only
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
Metabolic
Route
Subcutaneous
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
~5-10 mg/week, or ~1 mg/day SC (community; no validated dose)
Titration
None established
Reconstitution — illustrative, not a recommendation
10 mg vial + 2 mL BAC = 5 mg/mL; 1 mg = 20 U, 5 mg = 100 U on U-100. Vendor 10mg/1mL guides HALVE the units - always recompute.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. WADA S4.4 (AMPK activator) prohibited at all times.
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 (15 Apr 2026)
PCAC review
2026-07-23/24
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows

Robust preclinical; only human exposure was an ANALOG (CB4211, discontinued). Native MOTS-c efficacy unproven; Phase 2a recruiting (primary completion ~Feb 2027).

04Safety
Contraindications
  • Active/history of cancer (AMPK modulation; precautionary)
  • Pregnancyhard stop
  • WADA athletes
  • Diabetics on insulin/secretagogues (supervision)
Key interactions
  • Insulin/sulfonylureas/GLP-1 -> additive glucose-lowering (hypoglycemia)
Serious signals
  • No human safety trial of native MOTS-c
  • Injection-site reactions (analog data)
Monitoring
Glucose if combined with glucose-lowering agents; no validated cadence.
05Related in Metabolic
Semaglutide
FDA-approved RCTs
grade A →
Tirzepatide
FDA-approved RCTs
grade A →
Retatrutide
human trials
grade B →
Cagrilintide / CagriSema
human trials
grade B →
06Sources
1ClinicalTrials.gov NCT07505745
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium
← All peptides
Metabolic

MOTS-c

mitochondrial-derived peptide

Rising longevity/biohacker name; 'exercise mimetic'; first native human RCT (Phase 2a, NCT07505745) began Feb 2026.

Evidence
D
animal-only
Status
Removed from Cat 2 · pending PCAC
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous
Community / anecdotal
Demand
—
honorable mention
WADA
Prohibited
tested athletes — avoid
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

~5-10 mg/week, or ~1 mg/day SC (community; no validated dose)

Worked reconstitution example

10 mg vial + 2 mL BAC = 5 mg/mL; 1 mg = 20 U, 5 mg = 100 U on U-100. Vendor 10mg/1mL guides HALVE the units - always recompute.

Titration

None established

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. WADA S4.4 (AMPK activator) prohibited at all times.
StatusRemoved from Cat 2 · pending PCAC
503A bulksNot on the bulks list
Category 2 (2026)Removed from Category 2 (15 Apr 2026)
PCAC review2026-07-23/24
WADAProhibited (S0)
03

Evidence — the honest read

Danimal-only

Robust preclinical; only human exposure was an ANALOG (CB4211, discontinued). Native MOTS-c efficacy unproven; Phase 2a recruiting (primary completion ~Feb 2027).

04

Safety

Contraindications
  • Active/history of cancer (AMPK modulation; precautionary)
  • Pregnancyhard stop
  • WADA athletes
  • Diabetics on insulin/secretagogues (supervision)
Key interactions
  • Insulin/sulfonylureas/GLP-1 -> additive glucose-lowering (hypoglycemia)
Serious signals
  • No human safety trial of native MOTS-c
  • Injection-site reactions (analog data)
Monitoring

Glucose if combined with glucose-lowering agents; no validated cadence.

06

Sources

01ClinicalTrials.gov NCT07505745
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium